Advertisement
Screener

Vivos Therapeutics, Inc. (VVOS) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Vivos Therapeutics, Inc. Financing Cash Flow

Vivos Therapeutics, Inc. (VVOS) reported Financing Cash Flow of $9.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14

  • Vivos Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $3.23M.
  • Vivos Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $6.11M.
  • Vivos Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.33M, a 41.94% increase year-over-year.
  • Vivos Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $2.76M, a 27.04% decline year-over-year.
  • Vivos Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $18.56M, a 3.82% increase from fiscal 2024.
  • Vivos Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $17.88M, a 63.65% increase from fiscal 2023.
  • Vivos Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $10.92M.
  • Vivos Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $24.17M, a 2.68% increase from fiscal 2020.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 6 month as first filedNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 9 month as first filedNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 12 month as first filed
2026-06-30$3.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14
$9.34M
10-Q · filed 2026-08-14
$13.67M
derived: sum of 3 quarters · filed 2026-08-14
$16.43M
derived: sum of 4 quarters · filed 2026-08-14
2026-03-31$6.11M
10-Q · filed 2026-05-20
$10.44M
derived: sum of 2 quarters · filed 2026-05-20
$13.21M
derived: sum of 3 quarters · filed 2026-05-20
2025-12-31$4.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
$7.10M
derived: sum of 2 quarters · filed 2026-04-15
$18.56M
10-K · filed 2026-04-15
2025-09-30$2.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19
$14.22M
10-Q · filed 2025-11-19
2025-06-30$11.46M
10-Q · filed 2026-08-14
2024-12-31$3.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15
$6.84M
derived: sum of 2 quarters · filed 2026-04-15
$14.24M
derived: sum of 3 quarters · filed 2026-04-15
$17.88M
10-K · filed 2026-04-15
2024-09-30$3.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19
$11.19M
derived: sum of 2 quarters · filed 2025-11-19
$14.82M
10-Q · filed 2025-11-19
$18.39M
derived: sum of 4 quarters · filed 2025-11-19
2024-06-30$7.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19
$11.04M
10-Q · filed 2025-08-19
$14.60M
derived: sum of 3 quarters · filed 2025-08-19
$14.60M
derived: sum of 4 quarters · filed 2025-08-19
2024-03-31$3.63M
10-Q · filed 2025-05-15
$7.20M
derived: sum of 2 quarters · filed 2025-05-15
$7.20M
derived: sum of 3 quarters · filed 2025-05-15
$7.20M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31$3.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31
$3.57M
derived: sum of 2 quarters · filed 2025-03-31
$3.57M
derived: sum of 3 quarters · filed 2025-03-31
$10.92M
10-K · filed 2025-03-31
2023-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$0.00
derived: sum of 2 quarters · filed 2024-11-14
$7.36M
10-Q · filed 2024-11-14
2023-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$7.36M
10-Q · filed 2024-08-14
2023-03-31$7.36M
10-Q · filed 2024-05-14
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
-$1.17M
derived: sum of 2 quarters · filed 2023-03-30
$24.19M
derived: sum of 3 quarters · filed 2023-03-30
$24.17M
10-K · filed 2023-03-30
2021-09-30-$1.17M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-12-20
$24.19M
derived: sum of 2 quarters · filed 2022-12-20
$24.17M
10-Q · filed 2022-12-20
$24.17M
10-Q · filed 2021-11-15
$44.54M
derived: sum of 4 quarters · filed 2022-12-20
2021-06-30$25.37M
derived: 10-Q 6 month − 10-Q/A 3 month · filed 2022-12-20
$25.34M
10-Q · filed 2022-12-20
$25.34M
10-Q · filed 2021-08-12
$45.71M
derived: sum of 3 quarters · filed 2022-12-20
$47.53M
derived: sum of 4 quarters · filed 2022-12-20
2021-03-31-$25.00K
10-Q/A · filed 2022-11-25
$20.34M
derived: sum of 2 quarters · filed 2022-11-25
$22.17M
derived: sum of 3 quarters · filed 2022-11-25
$23.43M
derived: sum of 4 quarters · filed 2022-11-25
2020-12-31$20.37M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
$22.19M
derived: sum of 2 quarters · filed 2022-03-31
$23.46M
derived: sum of 3 quarters · filed 2022-03-31
$23.54M
10-K · filed 2022-03-31
$23.54M
10-K · filed 2021-03-25
2020-09-30$1.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$3.09M
derived: sum of 2 quarters · filed 2021-11-15
$3.17M
10-Q · filed 2021-11-15
2020-06-30$1.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$1.34M
10-Q · filed 2021-08-12
2020-03-31$79.52K
10-Q · filed 2021-05-17
2019-12-31$4.47M
10-K · filed 2021-03-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Beyond Air, Inc. (XAIR)United States$0.003B-0.01
NEXGEL, INC. (NXGL)United States$0.002B
INVO Fertility, Inc. (IVF)United States$0.002B-0.71
Catheter Precision, Inc. (VTAK)United States$0.002B-0.23
Tenon Medical, Inc. (TNON)United States$0.002B
Autonomix Medical, Inc. (AMIX)United States$0.004B
Adagio Medical Holdings, Inc. (ADGM)United States$0.004B
Profusa, Inc. (PFSA)United States$0.002B
OSR Health, Inc. (OSRH)United States$0.004B-0.75
Bluejay Diagnostics, Inc. (BJDX)United States$0.004B